Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate safety, tolerability, and
pharmacokinetics of BI 201335 ZW following administration of single rising doses from 5 mg to
1500 mg. In addition Two stage intra-subject bioavailability comparison of 600 mg BI 201335
ZW as a liquid formulation given with and without food.